Author

S. G. Gaffney

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Research Focus:variant effect prediction· 2 Assay:whole-exome sequencing· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:variant calling· 1

Frequent Co-Authors

J. P. Townsend· 2 shared V. L. Cannataro· 2 shared A. Greenstein· 1 shared C. Stender· 1 shared M. Philips· 1 shared Z.-M. Zhao· 1 shared

Activity by Year

2017-2018 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. P. Townsend

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivFeb 27, 2018

Effect sizes of somatic mutations in cancer

V. L. Cannataro, S. G. Gaffney, J. P. Townsend

The paper estimates effect sizes of recurrent single nucleotide variants in 23 cancer types to quantify their relative importance in cancer growth and therapeutic response.

DOI 10.1093/jnci/djy168

humanwhole-exome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivJun 13, 2017

The likelihood of heterogeneity or additional mutation in KRAS or associated oncogenes to compromise targeting of oncogenic KRAS G12C

V. L. Cannataro, S. G. Gaffney, C. Stender…·J. P. Townsend

The study finds no evidence of resistance-conferring mutations in KRAS or downstream genes in KRAS G12C positive tumors at treatment time, and predicts BRAF mutations as likely resistance mechanisms with existing therapies.

DOI 10.1038/s41388-017-0105-z

humanwhole-exome sequencing

𝕏 PostBluesky